Company
Alixia Therapeutics
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients' lives.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- San Francisco, CA, United States
Claim, correct or request removal
Record updated 28 September 2026
About
Our lead compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatment
Funding snapshot
- Total raised
- $1.8MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $1.8M2024-07-09
Funding rounds
- Round, 2024
- $1.8M2024-07-09, SEC form D sold, 19 investors
Loading relationship preview